A First‐in‐man Safety and Pharmacokinetics Study of Nangibotide, a New Modulator of Innate Immune Response Through TREM‐1 Receptor Inhibition

The peptide nangibotide is the first clinical‐stage agent targeting the immunoreceptor TREM‐1 (triggering receptor expressed on myeloid cells‐1) and is being investigated as a novel therapy for acute inflammatory disorders such as septic shock. This first‐in‐man, randomized, double‐blind, ascending dose, placebo‐controlled Phase I study evaluated the safety, tolerability and pharmacokinetics of nangibotide.